Pharma Mar SA (ES:PHM)
BME:PHM
Want to see ES:PHM full AI Analyst Report?
PHM Stock Chart & Stats
€97.35
€0.65(0.83%)
At close: 4:00 PM EST
€97.35
€0.65(0.83%)
Day’s Range― - ―
52-Week Range€70.10 - €102.40
Previous CloseN/A
Volume4.24K
Average Volume (3M)74.16K
Market Cap
€1.68B
Enterprise Value€1.71B
Total Cash (Recent Filing)€167.22M
Total Debt (Recent Filing)€49.41M
Price to Earnings (P/E)17.2
Beta0.89
Next Earnings
Aug 05, 2026EPS Estimate
1.67Next Dividend Ex-DateN/A
Dividend Yield1.04%
Share Statistics
EPS (TTM)N/A
Shares Outstanding18,000,000
10 Day Avg. Volume71,270
30 Day Avg. Volume74,161
Financial Highlights & Ratios
PEG Ratio0.09
Price to Book (P/B)5.12
Price to Sales (P/S)5.82
P/FCF Ratio29.46
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€120.50Price Target Upside23.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)2.65
Revenue Forecast (FY)€228.72M
Bulls Say, Bears Say
Bulls Say
Revenue And Profit RecoveryA sustained rebound in top-line and net income (revenues +27% and net income +187% in 2025) indicates stronger demand and better commercial execution. This improvement underpins durable operating leverage, supports reinvestment in launches and reduces the immediate need for external financing over the next several quarters.
Stronger Cash Generation And Balance SheetMaterial positive operating cash flow and a healthy cash/investment buffer provide durable financial optionality: funding EU launches, sustaining R&D, and absorbing commercial spend increases without forced capital raises. Conservative leverage improves resilience to trial or launch timing variability.
Regulatory And Pipeline CatalystsNear‑term regulatory milestones and advancing pivotal trials are structural growth drivers: EU approval and staged launches materially expand addressable markets, while multiple late‑stage programs (LAGOON, SaLuDo, PM54) provide sequential catalyst potential to diversify revenue beyond legacy products.
Bears Say
Multi‑year Earnings And Cashflow VolatilityHistoric swings in profits and free cash flow reduce forecasting reliability and raise execution risk for launches and trials. Volatility can increase the company’s effective financing cost, force precautionary cash hoarding, and limit management's ability to commit to sustained commercial investments or dividends.
Dependence On Partners For Key MarketsHeavy reliance on external partners transfers execution risk and reduces revenue visibility: partner-controlled launches, inventory, and disclosures constrain PharmaMar’s ability to manage timing, pricing and market access, making realized royalties and milestone timing materially uncertain over the medium term.
Generic Competition For YondelisEstablished generic entrants in Europe have structurally reduced pricing power and royalties for Yondelis, and potential U.S. generics pose further downside. This structural erosion of a legacy revenue stream increases reliance on new approvals and pipeline launches to replace lost recurring income.
Pharma Mar SA News
PHM FAQ
What was Pharma Mar SA’s price range in the past 12 months?
Pharma Mar SA lowest stock price was €70.10 and its highest was €102.40 in the past 12 months.
What is Pharma Mar SA’s market cap?
Pharma Mar SA’s market cap is €1.68B.
When is Pharma Mar SA’s upcoming earnings report date?
Pharma Mar SA’s upcoming earnings report date is Aug 05, 2026 which is in 99 days.
How were Pharma Mar SA’s earnings last quarter?
Currently, no data Available
Is Pharma Mar SA overvalued?
According to Wall Street analysts Pharma Mar SA’s price is currently Undervalued.
Does Pharma Mar SA pay dividends?
Pharma Mar SA pays a Annually dividend of €0.8 which represents an annual dividend yield of 1.04%. See more information on Pharma Mar SA dividends here
What is Pharma Mar SA’s EPS estimate?
Pharma Mar SA’s EPS estimate is 1.67.
How many shares outstanding does Pharma Mar SA have?
Pharma Mar SA has 18,000,000 shares outstanding.
What happened to Pharma Mar SA’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Pharma Mar SA?
Currently, no hedge funds are holding shares in ES:PHM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharma Mar SA Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€120.50 (23.78% Upside)
€120.50 (23.78% Upside)
Insider Transactions
Bought Shares
Worth €10.3K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
27.08%
12-Months-Change
Fundamentals
Return on Equity
35.36%
Trailing 12-Months
Asset Growth
28.31%
Trailing 12-Months
Company Description
Pharma Mar SA
Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles of marine origin for use in oncology in Spain, Italy, Germany, Ireland, rest of EU, the United States, and internationally. The company operates through three segments: Oncology, Diagnostics, and RNA interference. It develops and commercializes Yondelis for the treatment of soft tissue sarcomas and for ovarian cancer; Aplidin for treating multiple myeloma; and Zepzelca for treating patients with small cell lung cancer. The company also develops PM14 which is in phase II clinical trails for the treatment of solid tumors. In addition, it develops and markets diagnostics kits; and develops drugs with therapeutic activity based on reducing or silencing gene expression. The company was incorporated in 1986 and is based in Madrid, Spain.
PHM Company Deck
PHM Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call communicated a strong set of financial results and clear strategic progress—notably robust revenue growth (+27% y/y), a material improvement in profitability (EBITDA ~5x; net income +187%), healthy cash generation (EUR 53m) and multiple regulatory/commercial advances for Zepzelca and other assets. Pipeline momentum (LAGOON, SaLuDo, PM54, PM534) and licensing deals (e.g., Merck for Japan) provide additional upside. Offsetting factors include a 12% decline in U.S. Zepzelca royalties driven by FX and competition, outstanding pricing/reimbursement negotiations in Europe, exposure to partner-controlled disclosures, generics risk for Yondelis, and planned increases in commercial spending. Overall, positive operational and financial trends materially outweigh the identified risks, though execution on European launches and partner dynamics will be key to sustaining momentum.View all ES:PHM earnings summariesPHM Stock 12 Month Forecast
Average Price Target
€120.50
▲(23.78% Upside)
Technical Analysis
Laboratorios Farmaceuticos Rovi
―
Oryzon Genomics SA
―
ADL Bionatur Solutions SA
―
1nKemia IUCT Group SA
―
Atrys Health SA
―
Options Prices
Currently, No data available
---